The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Open accessAbstract
Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to achieve full syndromal and functional recovery with the index and subsequent pharmacological treatments. Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset efficacy in major depressive disorder. Nevertheless, concerns remain about the safety and tolerability of ketamine and esketamine in mood disorders. Moreover, there is uncertainty about the appropriate position of these agents in treatment algorithms, their comparative effectiveness, and the appropriate setting, infrastructure, and personnel required for their competent and safe implementation. In this article, an international group of mood disorder experts provides a synthesis of the literature with respect to the efficacy, safety, and tolerability of ketamine and esketamine in adults with treatment-resistant depression. The authors also provide guidance for the implementation of these agents in clinical practice, with particular attention to practice parameters at point of care. Areas of consensus and future research vistas are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Available evidence also indicates that the efficacy of ketamine/esketamine in the acute treat ment of TRD is also apparent in individuals with greater de grees of antidepressant resistance 205 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [205]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The risks for the foregoing safety concerns would be expected to be mitigated when administering ketamine/esketamine under medical supervision in accordance with best practices 205 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [205]
In the citing paper
“This result is in line with a recent review of literature emphasising that tolerance of ketamine is good.32”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationMcIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citation
Research works printed but not linked: 12
- Toljan K, 2018, Med Sci (Basel), 6, 82
- Lin F, 2015, Int J Clin Exp Med, 8, 4335
- Szarmach J, 2019, Psychiatr Danub, 31, 585
- Andrade C, 2019, J Clin Psychiatry, 80, 19f12820
- Canuso CM, 2019, Focus Am Psychiatr Publ, 17, 55
- Wei YB, 2013, Hong Kong Med J, 19, 341
- Morgan CJA, 2004, Psychopharmacology (Berl), 172, 298
- Health Quality Ontario, 2016, Ont Health Technol Assess Ser, 16, 1
- Rodrigues NB, CNS Spectr
- Ng J, Psychopharmacology (Berl)
- Rodrigues NB, CNS Spectr
- Lipsitz O, CNS Spectr
Cited by
Sorted by citations
Items 101–200 of 730
Mechanisms of Action of Ketamine and Esketamine
Schatzberg, A. F. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21060653 · Cited by 28
Le, T. T., Vincenzo, J. D. D., Teopiz, K. M., Lee, Y. L., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R., Cao, B., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114231 · Cited by 27
Self-citationChubbs, B., Wang, J. C.-C., Archer, S., Chrenek, C., Khullar, A., Wolowyk, M., & Swainson, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1016439 · Cited by 27
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 29
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Pepe, M., Bartolucci, G., Marcelli, I., Pesaresi, F., Brugnami, A., Caso, R., Fischetti, A., Grisoni, F., Mazza, M., Camardese, G., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13101494 · Cited by 27
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 34
Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed PatientsPreprint
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · medRxiv · doi:10.1101/2023.04.28.23289210 · Cited by 26
Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. K., & Swainson, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1283733 · Cited by 26
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Lewis, V., Rurak, G. M., Salmaso, N., & Aguilar‐Valles, A. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2023.12.004 · Cited by 31
Ma, S., Dou, Y., Wang, W., Wei, A., Lan, M., Liu, J., Yang, L., & Yang, M. (2024) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2023.101241 · Cited by 28
Zhou, Y., Wang, C., Lan, X., Zheng, W., Li, H., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.10.037 · Cited by 25
Self-citationFugger, G., Bartova, L., Fabbri, C., Fanelli, G., Dold, M., Swoboda, M. M. M., Kautzky, A., Zohar, J., Souery, D., Mendlewicz, J., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01368-3 · Cited by 26
Self-citationSex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Benitah, K. C., Siegel, A. N., Lipsitz, O., Rodrigues, N. B., Meshkat, S., Lee, Y. L., Mansur, R. B., Nasri, F., Lui, L. M. W., McIntyre, R. S., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114579 · Cited by 24
Self-citationThe separation distress hypothesis of depression – an update and systematic review
Watt, D. F. (2023) · Neuropsychoanalysis · doi:10.1080/15294145.2023.2240340 · Cited by 25
Reyes-Lizaola, S., Luna-Zarate, U., Tendilla‐Beltrán, H., Morales‐Medina, J. C., & Flores, G. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110876 · Cited by 26
McIntyre, R. S. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21080814 · Cited by 23
Self-citationMathai, D. S., Hull, T. D., Vando, L., & Malgaroli, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.131 · Cited by 27
de Albuquerque, T. R., Macedo, L. F. R., Delmondes, G. D. A., Neto, M. L. R., Almeida, T. M., Uchida, R. R., Cordeiro, Q., Lisboa, K. W. D. S. C., & de Menezes, I. R. A. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221116477 · Cited by 24
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 24
Wong, S., Kwan, A. T. H., Teopiz, K. M., Le, G. H., Meshkat, S., Ho, R., d’Andrea, G., Cao, B., Vincenzo, J. D. D., Rosenblat, J. D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.142 · Cited by 24
Self-citationColla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.002 · Cited by 22
Trends and characteristics in ketamine use among US adults with and without depression, 2015–2022
Yang, K. H., Kepner, W. E., Cleland, C. M., & Palamar, J. J. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.108 · Cited by 22
Beaglehole, B., Glue, P., Neehoff, S., Shadli, S. M., McNaughton, N., Kimber, B., Muirhead, C., de Bie, A., Day-Brown, R., & Medlicott, N. J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251344710 · Cited by 22
Montano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 26
Esketamine and neurocognitive disorders in adult surgical patients: a meta-analysis
Xing, L., Liu, X., Huang, H., Xu, X., Zhang, T., & Gao, J. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02803-3 · Cited by 21
Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 21
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Levinta, A., Meshkat, S., McIntyre, R. S., Ho, C., Lui, L. M. W., Lee, Y. L., Mansur, R. B., Teopiz, K. M., Rodrigues, N. B., Vincenzo, J. D. D., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.050 · Cited by 22
Self-citationClinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
Meshkat, S., Teopiz, K. M., Vincenzo, J. D. D., Bailey, J., Rosenblat, J. D., Ho, R., Rhee, T. G., Ceban, F., Kwan, A. T. H., Cao, B., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.027 · Cited by 21
Self-citationPsychiatric disorders associated with PCSK9 inhibitors: A real‐world, pharmacovigilance study
Deng, Z., Liu, J., Gong, H., Cai, X., Han, X., & Gao, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14522 · Cited by 20
Overcoming the myths of esketamine administration: different and not difficult
Buchmayer, F., & Kasper, S. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1279657 · Cited by 23
Self-citationYrondi, A., Javelot, H., Nobile, B., Boudieu, L., Aouizerate, B., Llorca, P., Charpeaud, T., Bennabi, D., Antoine Lefrere, A., & Samalin, L. (2024) · L Encéphale · doi:10.1016/j.encep.2023.11.029 · Cited by 22
Guoweng, N. I. U., ZHENG, X., Bigao, D. E. N. G., DU, Y. S., & Mei, Y. (2024) · Minerva Anestesiologica · doi:10.23736/s0375-9393.24.17703-6 · Cited by 23
d’Andrea, G., Cavallotto, C., Pettorruso, M., Lorenzo, G. D., Carullo, R., Berardis, D. D., Rosso, G., Barlati, S., Martiadis, V., Tamagnini, G., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116655 · Cited by 21
Self-citationKritzer, M. D., Pae, C., & Masand, P. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069749 · Cited by 20
Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
Gałuszko‐Węgielnik, M., Chmielewska, Z., Jakuszkowiak‐Wojten, K., Wiglusz, M. S., & Cubała, W. J. (2023) · Brain Sciences · doi:10.3390/brainsci13010142 · Cited by 21
Hack, L. M., Zhang, X., Heifets, B. D., Suppes, T. M., van Roessel, P., Yesavage, J. A., Gray, N. J., Hilton, R. A., Bertrand, C., Rodríguez, C. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42141-5 · Cited by 23
The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression
Wang, K., Huang, S., Fu, D., Yang, X., Ma, L., Zhang, T., Zhao, W., Deng, D., Ding, Y., Zhang, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14536 · Cited by 19
Voute, M., Lambert, C., Pereira, B., & Pickering, G. P. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14406 · Cited by 19
McIntyre, R. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2253144 · Cited by 19
Self-citationQuintanilla, B., Zarate, C. A., & Pillai, A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02507-7 · Cited by 21
Self-citationGutiérrez, G., Swainson, J., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116125 · Cited by 19
Saez, E., Erkoreka, L., Moreno-Calle, T., Berjano, B., González-Pinto, A. M., Basterreche, N., & Arrúe, A. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i7.884 · Cited by 20
Patents on Psychedelics: The Next Legal Battlefront of Drug DevelopmentPreprint
Marks, M., & Cohen, I. G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3948757 · Cited by 19
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Kir4.1 Dysfunction in the Pathophysiology of Depression: A Systematic Review
Vecchia, S. D., Marchese, M., Santorelli, F. M., & Sicca, F. (2021) · Cells · doi:10.3390/cells10102628 · Cited by 18
Time of day influences stress hormone response to ketamine
Birnie, M. T., Eapen, A. V., Kershaw, Y. M., Lodge, D., Collingridge, G. L., Conway-Campbell, B. L., & Lightman, S. L. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13194 · Cited by 18
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 20
Yang, T., Mudabbar, M. S., Liu, B., Xu, M., & Fu, Q. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06676-2 · Cited by 18
Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone
Albert, U., Tomasetti, C., Marra, C., Neviani, F., Pirani, A., Taddeo, D., Zanetti, O. O., & Maina, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207621 · Cited by 18
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 22
Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
Dębowska, W., Więdłocha, M., Dębowska, M. D., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267647 · Cited by 23
Yang, J.-R., Li, Y.-Y., Ran, T., Lin, X., Xu, J.-Y., Zhou, S., & Huang, P. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s460924 · Cited by 18
Barrios, K. P., Connolly, D. J., Ferris, J., Maier, L. J., Barratt, M. J., WINSTOCK, A. R., Puljević, C., & Gilchrist, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241273850 · Cited by 20
Wang, J. X., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Rhee, T. G., Ho, R., Lo, H. K. Y., Goldberg, J. F., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119487 · Cited by 20
Self-citationVanicek, T., Unterholzner, J., Lanzenberger, R., Naderi-Heiden, A., Kasper, S., & Praschak-rieder, N. (2022) · World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2031287 · Cited by 15
Self-citationWang, J., Zeng, J., Zhao, N., Chen, S. C., Chen, Z., Liao, J., Ran, H., & Yu, C. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000340 · Cited by 17
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
Conway, C. R., Aaronson, S. T., Sackeïm, H. A., Duffy, W. J., Stedman, M., Quevedo, J., Allen, R. M., Riva‐Posse, P., Berger, M. A., Alva, G., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.03.016 · Cited by 19
Self-citationThe Co-occurrence of Depression and Obesity
McIntyre, R. S. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24com15322 · Cited by 18
Self-citationDong, C., Tian, Z. R., Fujita, Y., Fujita, A., Hino, N., Iijima, M., & Hashimoto, K. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173316 · Cited by 17
Mapping consent practices for outpatient psychiatric use of ketamine
Mathai, D. S., Lee, S. M., Mora, V., O’Donnell, K. C., Garcia‐Romeu, A., & Storch, E. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.036 · Cited by 16
Biomarkers for Deep Brain Stimulation in Animal Models of Depression
Yuen, J., Rusheen, A. E., Price, J. B., Barath, A. S., Shin, H., Kouzani, A. Z., Berk, M., Blaha, C. D., Lee, K. H., & Oh, Y. (2021) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13483 · Cited by 16
Self-citationRobison, R., Brendle, M., Moore, C., Cross, H. L., Helm, L., Darling, S., Thayer, S. D., Thielking, P., & Shannon, S. M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2186285 · Cited by 17
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality
Mathai, D. S., McCathern, A. G., Guzick, A. G., Schneider, S. C., Weinzimmer, S. A., Cepeda, S. L., Garcia‐Romeu, A., & Storch, E. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0078 · Cited by 18
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Ruhé, H. G., Rot, M. A. H., Kamphuis, J., de Boer, M. K., & Schoevers, R. A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1059 · Cited by 17
Ledwos, N., Rosenblat, J. D., Blumberger, D. M., Castle, D. J., McIntyre, R. S., Mulsant, B. H., & Husain, M. I. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001608 · Cited by 18
Self-citationInterventional Psychiatry and Neurotechnologies: Education and Ethics Training
Giacobbe, P., Burhan, A. M., Waxman, R. E., & Ng, E. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.27 · Cited by 16
Spurny‐Dworak, B., Godbersen, G. M., Reed, M. B., Unterholzner, J., Vanicek, T., Baldinger, P., Hahn, A., Kranz, G. S., Bogner, W., Lanzenberger, R. R., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.913274 · Cited by 17
Self-citationPronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
Aguilar, A. G., Beauregard, B. A., Conroy, C. P., Khatiwoda, Y. T., Horsford, S. M. E., Nichols, S. D., & Piper, B. J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2178558 · Cited by 15
Wilkowska, A., & Cubała, W. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1322752 · Cited by 15
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 15
Taraku, B., Loureiro, J. R., Sahib, A. K., Zavaliangos‐Petropulu, A., Al‐Sharif, N., Leaver, A. M., Wade, B., Joshi, S. H., Woods, R. P., Espinoza, R. T., et al. (2024) · Brain and Behavior · doi:10.1002/brb3.3511 · Cited by 15
Zeng, Q.-B., Zou, D.-C., Huang, X.-B., Shang, D.-W., Huang, X., Yang, X.-H., Ning, Y.-P., Balbuena, L., Xiang, Y.-T., & Zheng, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.038 · Cited by 15
Zhou, Y., Wang, C., Lan, X., Li, W., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.779326 · Cited by 16
Self-citationYip, R., Swainson, J., Khullar, A., McIntyre, R. S., & Skoblenick, K. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1017504 · Cited by 16
Self-citationKetamine use in pediatric depression: A systematic review
Meshkat, S., Rosenblat, J. D., Ho, R., Rhee, T. G., Cao, B., Ceban, F., Danayan, K., Chisamore, N., Vincenzo, J. D. D., & McIntyre, R. S. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114911 · Cited by 16
Self-citationCurrent approaches to precision medicine in psychiatry: Are we just spinning our wheels?
Dean, O. M., & Walker, A. J. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.003 · Cited by 15
Jiang, Q., Qi, Y., Zhou, M., Dong, Y., Zheng, W., Zhu, L., Li, Y., Zhou, H., & Wang, L. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02681-9 · Cited by 14
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Kwan, A. T. H., Lakhani, M., Teopiz, K. M., Wong, S., Le, G. H., Ho, R., Rhee, T. G., Cao, B., Rosenblat, J. D., Mansur, R. B., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.054 · Cited by 14
Self-citationEffects of ketamine on postoperative cognition: a scoping review
Brenna, C. T. A., He, X., Liu, D., Kaustov, L., Choi, S., & Orser, B. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.035 · Cited by 15
Zhang, J., Xie, S., Chen, Y., Zhou, X., Zheng, Z., Yang, L., & Li, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1008124 · Cited by 14
Chisamore, N., Danayan, K., Rodrigues, N. B., Vincenzo, J. D. D., Meshkat, S., Doyle, Z., Mansur, R. B., Phan, L., Fancy, F., Chau, E. H., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231171531 · Cited by 15
Self-citationJoseph, B., Núñez, N. A., Kung, S., Voort, J. L. V., Pazdernik, V., Schak, K. M., Boehm, S. M., Carpenter, B., Johnson, E. K., Malyshev, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081164 · Cited by 14
Azevedo, N., da Silva, M. O., & Madeira, L. (2023) · Philosophies · doi:10.3390/philosophies8050076 · Cited by 15
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14
Parikh, S. V., Voort, J. L. V., Yocum, A. K., Achtyes, E. D., Goes, F. S., Nykamp, L. J., Singh, B., Lopez-Vives, D., Sera, C. E., Maixner, D. F., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.033 · Cited by 15
Gutiérrez, G., Kang, M. J. Y., & Vázquez, G. H. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115865 · Cited by 15
Yin, X., Ke, Y., Liang, Y., Zhang, S., Chen, Z., Yu, L., Jiang, M., Liu, Q., & Gu, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401373 · Cited by 15
Cheng, M. C. H., Dri, C. E., Ballum, H., Valentino, K., Cheung, W., Teopiz, K. M., Wong, S., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.119 · Cited by 15
Self-citationSforzini, L. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100331 · Cited by 14
Riggs, L. M., Thompson, S. M., & Gould, T. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109153 · Cited by 15
Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series
Tham, J. C. W., Do, A., Fridfinnson, J. A., Rafizadeh, R., Siu, J. T. P., Budd, G. P., & Lam, R. W. M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000409 · Cited by 14
Carboni, E., & Carta, A. R. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2105144 · Cited by 16
Weiss, M., & Siegmund, W. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.993 · Cited by 13
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 13
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis
Elmosalamy, A., Tarikogullari, I., Patarroyo-Rodríguez, L., Wilson, G., Voort, J. L. V., Kung, S., Frye, M. A., & Singh, B. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251394127 · Cited by 14
Berens, N., & Kim, S. Y. H. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.07.003 · Cited by 13
Pepe, M., Bartolucci, G., Marcelli, I., Simonetti, A., Camardese, G., Nicola, M. D., & Sani, G. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000723 · Cited by 13
Metadata
- Authors
- McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A. H., Zarate, C. A., & Stahl, S.
- Affiliations
- University Health Network (CA)
- Mood Disorders Psychopharmacology Unit, University Health Network, Toronto (McIntyre, Rosenblat, Y. Lee, Lui, Mansur); Department of Psychiatry, University of Toronto, Toronto (McIntyre, Rosenblat, Mansur); Department of Pharmacology, University of Toronto, Toronto (McIntyre); Brain and Cognition Discovery Foundation, Toronto (McIntyre, Subramaniapillai); Canadian Rapid Treatment Center of Excellence, Mississauga, Ontario (Rosenblat, Kratiuk); Department of Psychiatry and Behavioral Sciences, Austin Dell...
- ORCID
- McIntyre, Roger S.
- Rosenblat, Joshua D.
- Nemeroff, Charles B.
- Sanacora, Gerard
- Murrough, James W.
- Brietzke, Elisa
- Dodd, Seetal
- Gorwood, Philip
- Ho, Roger
- Iosifescu, Dan V.
- Kasper, Siegfried
- Kratiuk, Kevin
- Lee, Jung Goo
- Lee, Yena
- Lui, Leanna M.W.
- Mansur, Rodrigo B.
- Papakostas, George I.
- Subramaniapillai, Mehala
- Thase, Michael
- Vieta, Eduard
- Young, Allan H.
- Zarate, Carlos A.
- Stahl, Stephen
- Venue
- American Journal of Psychiatry
- Published
- 2021-05-01
- Volume
- 178
- Issue
- 5
- Pages
- 383-399
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC9635017
- OpenAlex
- W3137976016
- Semantic Scholar
- 3cd087ef6947b39c8c924b7248d9d40de77b9e44
- Cited by
- 731
- References
- 168
- Citations by year
- 2026: 129 · 2025: 167 · 2024: 165 · 2023: 141 · 2022: 83 · 2021: 44
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NIHR202380)
- National Institutes of Health (Z99 MH999999)
- National Institute of Mental Health (ZIAMH002857, ZIAMH002927)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, treatment-resistant depression, major depressive disorder, drug safety and tolerability, clinical implementation, treatment algorithm, expert consensus
- MeSH terms
- Implementation Science, Antidepressive Agents, Delivery of Health Care, Depressive Disorder, Major, Major Depressive Disorder, Dissociative Disorders, Humans, Hypertension, Ketamine, Monitoring, Physiologic, Personnel Staffing and Scheduling, Psychoses, Substance-Induced, Patient Selection, Excitatory Amino Acid Antagonists, Substance-Related Disorders, Suicidal Ideation, Lower Urinary Tract Symptoms, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
